In a boost for Sarepta Therapeutics (SRPT), the last remaining large health insurer has agreed to cover its pricey treatment for a rare form of muscular dystrophy.

In a policy bulletin issued on Thursday, Anthem (ANTM) declared Exondys 51 to be “medically necessary,” reversing a decision made a year ago not to reimburse the drug, which had just been approved to treat Duchenne muscular dystrophy amid controversy about underlying clinical data.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • My son Shivam Anjay age 19 years patient of DMD needs treatment by sarepta Exondys 51, when this medicine will be available in India or if I want to get treatment at USA what cost I have to bear, pl help and guide me.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy